InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,276.40
(
-0.68%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.01
(
0.37%
)
Bitcoin
64,994.11
(
0.04%
)
Post# of 252274
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: ghmm post# 117378

Thursday, 03/31/2011 4:10:49 PM

Thursday, March 31, 2011 4:10:49 PM

Post# of 252274
On top of what you've mentioned, I also have confidence in management and their experience in bringing ERTs to the market. They need to enroll patients carefully as too severe ones will have advanced skeletal defects and will probably not improve on 6MWT during the trial. I don't see any reason why GALNS should have different injection site reactions than other ERTs.

I don't think PLX will spoil the nice statistics for ERT's to enter Phase 3, and will be approved :)
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up